Tenax Therapeutics Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Chris Giordano
Chief executive officer
US$644.8k
Total compensation
| CEO salary percentage | 62.9% |
| CEO tenure | 3.4yrs |
| CEO ownership | n/a |
| Management average tenure | 3.4yrs |
| Board average tenure | 3.8yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$15m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$645k | US$405k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$667k | US$386k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$12m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$861k | US$183k | -US$32m |
Compensation vs Market: Chris's total compensation ($USD644.77K) is about average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Giordano (50 yo)
3.4yrs
Tenure
US$644,770
Compensation
Mr. Christopher T. Giordano, also known as Chris, has been the Chief Executive Officer and Director of Tenax Therapeutics, Inc. since joining on July 14, 2021 and serves as its President since October 29,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.4yrs | US$644.77k | no data | |
| Chief Medical Officer & Director | 3.9yrs | US$481.22k | 0.043% $ 8.2k | |
| Interim CFO and Principal Financial Officer & Principal Accounting Officer | no data | no data | no data | |
| Chief Business Officer | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | no data | no data | no data |
3.4yrs
Average Tenure
51yo
Average Age
Experienced Management: TENX's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.4yrs | US$644.77k | no data | |
| Chief Medical Officer & Director | 3.8yrs | US$481.22k | 0.043% $ 8.2k | |
| Independent Chairman | 10.7yrs | US$88.50k | 0.049% $ 9.4k | |
| Independent Director | 3.8yrs | US$57.50k | 0.085% $ 16.2k | |
| Member of PH-Left Heart Disease Scientific Advisory Board | 6.8yrs | no data | no data | |
| Independent Director | 3.8yrs | US$48.50k | 0.067% $ 12.8k | |
| Independent Director | 2.9yrs | US$65.00k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$59.50k | 0% $ 0 | |
| Member of PH-Left Heart Disease Scientific Advisory Board | 6.8yrs | no data | no data | |
| Member of PH-Left Heart Disease Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of PAH Scientific Advisory Board | no data | no data | no data | |
| Member of PAH Scientific Advisory Board | no data | no data | no data |
3.8yrs
Average Tenure
67yo
Average Age
Experienced Board: TENX's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:49 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tenax Therapeutics, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seamus Fernandez | Guggenheim Securities, LLC |
| Vernon Bernardino | H.C. Wainwright & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |